Clinical evidence summary
Durable BLOOD PRESSURE®
Durable
BLOOD PRESSURE®
Durable BLOOD PRESSURE was formulated by Dr. Kevin Passero based on 20 years of clinical practice—combining two patented, clinically validated extracts that work through complementary pathways to address the real drivers of high blood pressure.
Every ingredient is backed by peer-reviewed human clinical trials—selected not just for scientific validation, but for results that hold up in the real world.
Key clinical outcomes
What the research shows
↓ Systolic BP · Enovita®
−37 pts
Average systolic blood pressure reduction from baseline at 300mg daily over 16 weeks, combined with diet and lifestyle changes, in pre/mildly hypertensive adults.
Belcaro et al. 2013 · PMC3792515 ·
119 adults
↓ Diastolic BP · Enovita®
−9 pts
Average diastolic blood pressure reduction from baseline at 300mg daily over 16 weeks, combined with diet and lifestyle changes, in pre/mildly hypertensive adults.
Belcaro et al. 2013 · PMC3792515 ·
119 adults
↑ Nitric oxide · Enovita® (in vitro)
+154%
eNOS nitric oxide enzyme activation in endothelial cell model—explains vessel-relaxing mechanism.
Petrangolini et al. 2021 · PMC7922661 ·
HUVEC cell study
↓ Endothelin-1 · Enovita® (in vitro)
>80%
Endothelin-1—the peptide that constricts arteries—reduced to near-undetectable levels.
Petrangolini et al. 2021 · PMC7922661 ·
endothelial cell model
↓ Systolic BP · Benolea®
−11 pts
Reduction from baseline at 1,000mg daily over 8 weeks in borderline hypertensive identical twins.
Perrinjaquet-Moccetti et al. 2008 ·
monozygotic twin RCT · 8 weeks
↓ Systolic BP · Benolea®
−11.5 pts
Systolic BP reduction in 8-week double-blind active-controlled study in 232 stage-1 hypertensive patients.
Susalit et al. 2011 · Phytomedicine ·
232 patients · 8 weeks
↓ Systolic BP · Enovita®
−37 pts
Average systolic blood pressure reduction from baseline at 300mg daily over 16 weeks, combined with diet and lifestyle changes, in pre/mildly hypertensive adults.
Belcaro et al. 2013 · PMC3792515 · 119 adults
↓ Diastolic BP · Enovita®
−9 pts
Average diastolic blood pressure reduction from baseline at 300mg daily over 16 weeks, combined with diet and lifestyle changes, in pre/mildly hypertensive adults.
Belcaro et al. 2013 · PMC3792515 · compliance >94%
↑ Nitric oxide · Enovita® (in vitro)
+154%
eNOS nitric oxide enzyme activation in endothelial cell model—explains vessel-relaxing mechanism.
Petrangolini et al. 2021 · PMC7922661 · HUVEC cell study
↓ Endothelin-1 · Enovita® (in vitro)
>80%
Endothelin-1—the peptide that constricts arteries—reduced to near-undetectable levels.
Petrangolini et al. 2021 · PMC7922661 · endothelial cell model
↓ Systolic BP · Benolea®
−11 pts
Reduction from baseline at 1,000mg daily over 8 weeks in borderline hypertensive identical twins.
Perrinjaquet-Moccetti et al. 2008 · monozygotic twin RCT · 8 weeks
↓ Systolic BP · Benolea®
−11.5 pts
Systolic BP reduction in 8-week double-blind active-controlled study in 232 stage-1 hypertensive patients.
Susalit et al. 2011 · Phytomedicine · 232 patients · 8 weeks
Dual-ingredient mechanism
Two polyphenols, two pathways
Beyond blood pressure
Additional cardiovascular benefits
Clinical References
Enovita® · Registry Study · Primary BP Evidence
Belcaro et al., PMC3792515 · 2013
Controlled registry study. 119 pre- and mildly hypertensive adults. 150mg and 300mg vs. lifestyle-only control. 16 weeks. 93% BP normalization at 300mg. −37 points systolic, −9 points diastolic. Improved microcirculation. No side effects. Compliance >94%.
119 patients · 16 weeks · 93% efficacy
Enovita® · Mechanism + Double-Blind RCT
Petrangolini et al., PMC7922661 · 2021
HUVEC endothelial cell study (in vitro) + randomized, double-blind, placebo-controlled human RCT in 80 mild-hypertensive adults. 300mg/day for 16 weeks. BP significantly modulated vs. placebo. eNOS +154% and endothelin-1 reduced to near-undetectable (in vitro mechanism).
80 adults · Double-blind · In vitro mechanism
Benolea® · Twin Study · Dose-Dependent
Perrinjaquet-Moccetti et al. · 2008
Randomized controlled trial in monozygotic twin pairs with borderline hypertension. 500mg vs. 1,000mg Benolea® for 8 weeks. Dose-dependent response: max −13 points systolic and −5 points diastolic at 1,000mg. LDL significantly reduced. Improvements within 7 days.
Identical twins · Dose-dependent · 8 weeks
Benolea® · Active-Controlled · Stage-1 Hypertension
Susalit et al., Phytomedicine 2011
Randomized, double-blind, active-controlled. 232 stage-1 hypertension patients. 8 weeks. Significant reduction in systolic (−11.5 pts) and diastolic (−4.8 pts) blood pressure. Additionally reduced total cholesterol and triglycerides.
232 patients · Active-controlled · Double-blind
Grape Seed Extract · Meta-Analysis Confirmation
Zhang et al., Medicine 2016
Meta-analysis of 16 randomized controlled trials on grape seed extract and blood pressure. Significant systolic BP reduction confirmed across studies. Validates the broader OPC mechanism across diverse formulations and populations.
16 RCTs · Systolic BP confirmed
Olive Leaf Extract · Meta-Analysis · 12 RCTs
Hadi et al. 2022
Systematic review and meta-analysis of 12 RCTs. Confirmed blood pressure and triglyceride reductions across independent studies — consistent with both Benolea® human trials and supporting generalizability of results.
819 participants · 12 RCTs
Ready to Try Durable BLOOD PRESSURE?
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. "Points" refers to mmHg, the standard unit of blood pressure measurement. The −37 point systolic and −9 point diastolic reductions and 93% BP normalization rate are from Belcaro et al. 2013 (119 pre/mildly hypertensive adults, 16 weeks, 300mg Enovita®, registry study with concurrent lifestyle intervention). The +154% eNOS activation and >80% endothelin-1 reduction are from in vitro endothelial cell experiments — they describe the vasodilation mechanism, not a measured human outcome. The −13 point systolic figure is from the Perrinjaquet-Moccetti 2008 twin RCT (1,000mg Benolea®, 8 weeks). The −11.5 point result is from Susalit et al. 2011 (232 stage-1 hypertensive patients, active-controlled, 8 weeks). All results are population-specific and individual results may vary.
Clinical References
Enovita® · Registry Study · Primary BP Evidence
Belcaro et al., PMC3792515 · 2013
Controlled registry study. 119 pre- and mildly hypertensive adults. 150mg and 300mg vs. lifestyle-only control. 16 weeks. 93% BP normalization at 300mg. −37 points systolic, −9 points diastolic. Improved microcirculation. No side effects. Compliance >94%.
119 patients · 16 weeks · 93% efficacy
Enovita® · Mechanism + Double-Blind RCT
Petrangolini et al., PMC7922661 · 2021
HUVEC endothelial cell study (in vitro) + randomized, double-blind, placebo-controlled human RCT in 80 mild-hypertensive adults. 300mg/day for 16 weeks. BP significantly modulated vs. placebo. eNOS +154% and endothelin-1 reduced to near-undetectable (in vitro mechanism).
80 adults · Double-blind · In vitro mechanism
Benolea® · Twin Study · Dose-Dependent
Perrinjaquet-Moccetti et al. · 2008
Randomized controlled trial in monozygotic twin pairs with borderline hypertension. 500mg vs. 1,000mg Benolea® for 8 weeks. Dose-dependent response: max −13 points systolic and −5 points diastolic at 1,000mg. LDL significantly reduced. Improvements within 7 days.
Identical twins · Dose-dependent · 8 weeks
Benolea® · Active-Controlled · Stage-1 Hypertension
Susalit et al., Phytomedicine 2011
Randomized, double-blind, active-controlled. 232 stage-1 hypertension patients. 8 weeks. Significant reduction in systolic (−11.5 pts) and diastolic (−4.8 pts) blood pressure. Additionally reduced total cholesterol and triglycerides.
232 patients · Active-controlled · Double-blind
Grape Seed Extract · Meta-Analysis Confirmation
Zhang et al., Medicine 2016
Meta-analysis of 16 randomized controlled trials on grape seed extract and blood pressure. Significant systolic BP reduction confirmed across studies. Validates the broader OPC mechanism across diverse formulations and populations.
16 RCTs · Systolic BP confirmed
Olive Leaf Extract · Meta-Analysis · 12 RCTs
Hadi et al. 2022
Systematic review and meta-analysis of 12 RCTs. Confirmed blood pressure and triglyceride reductions across independent studies — consistent with both Benolea® human trials and supporting generalizability of results.
819 participants · 12 RCTs
Ready to Try Durable
BLOOD PRESSURE?
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. "Points" refers to mmHg, the standard unit of blood pressure measurement. The −37 point systolic and −9 point diastolic reductions and 93% BP normalization rate are from Belcaro et al. 2013 (119 pre/mildly hypertensive adults, 16 weeks, 300mg Enovita®, registry study with concurrent lifestyle intervention). The +154% eNOS activation and >80% endothelin-1 reduction are from in vitro endothelial cell experiments — they describe the vasodilation mechanism, not a measured human outcome. The −13 point systolic figure is from the Perrinjaquet-Moccetti 2008 twin RCT (1,000mg Benolea®, 8 weeks). The −11.5 point result is from Susalit et al. 2011 (232 stage-1 hypertensive patients, active-controlled, 8 weeks). All results are population-specific and individual results may vary.